secwatch.observer — SEC 8-K summary
======================================

Issuer:     Propanc Biopharma, Inc. (PPCB)
CIK:        0001517681
Form:       8-K
Filed at:   2026-07-14T20:01:28+00:00
Accession:  0001493152-26-033173
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Propanc Biopharma appoints Carlo Campiciano to Board, replacing retiring director Annie Van Broekhoven
--------------------------------------------------------------------------------

- Annie Van Broekhoven retired from Board effective July 8, 2026.
- Carlo Campiciano appointed to fill vacancy; he is a qualified accountant and former CFO of MedAdvisor.
- Director agreement provides $45,000 annual cash compensation paid quarterly.
- Equity compensation of 0.5% to 4.99% based on milestone achievements.
- Campiciano is independent per Nasdaq/NYSE American standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517681/000149315226033173/0001493152-26-033173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517681/000149315226033173/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-033173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer